Sean Richardson
General Manager, Alexion UK & Ireland
Alexion is a global biopharmaceutical company focused on transforming the lives of people affected by rare diseases and devastating conditions through the development and delivery of innovative medicines. We believe it is our responsibility to listen to, understand and help people living with rare disease and those who work tirelessly to offer care and support.
Every day, people living with rare diseases, and their caregivers and families, face the fear of the unknown with courage, tenacity and grace.
Rare diseases can be devastating. People impacted by rare conditions face major obstacles that can put them at a significant disadvantage, including delays in diagnosis, access to medicines, and fragmented care. Every day, people living with rare diseases, and their caregivers and families, face the fear of the unknown with courage, tenacity and grace, and that inspires us to continue to strive to do everything we can to help. They are our heros.
Our innovation, which fuels all of our efforts, happens in-house with our research and development team and externally with world-renowned collaborators. We are not afraid to take on challenges and are committed to exploring every opportunity that may make a difference. In these unprecedented times, it is even more important that our innovation is driven by a sense of urgency and a relentless quest for answers.
Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Our innovation is not limited to science and discovery. We actively seek opportunities to work more efficiently to provide the best experience for our stakeholders.
Alexion is a proud and committed partner to the rare disease community.
Through research and development, we’re building a better tomorrow, every day.
